AR120679A1 - Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar - Google Patents
Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliarInfo
- Publication number
- AR120679A1 AR120679A1 ARP200103391A ARP200103391A AR120679A1 AR 120679 A1 AR120679 A1 AR 120679A1 AR P200103391 A ARP200103391 A AR P200103391A AR P200103391 A ARP200103391 A AR P200103391A AR 120679 A1 AR120679 A1 AR 120679A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- hydrogen
- group
- bile acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente se refiere a los derivados 1,5-benzotiazepina y 1,2,5-benzotiadiazepina de la fórmula (1). Estos compuestos son moduladores del ácido biliar que tienen el transportador apical del ácido biliar dependiente del sodio (ASBT) y/o actividad inhibidora del transporte del ácido biliar del hígado (LBAT). También se refiere a composiciones farmacéuticas que comprenden estos compuestos y al uso de estos compuestos en el tratamiento de enfermedades cardiovasculares, metabolismo de ácidos grasos y trastornos debidos al uso de la glucosa, enfermedades gastrointestinales y enfermedades hepáticas. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado por que M se selecciona de -CH₂- y -NR⁷-; R¹ es alquilo C₁₋₄; R² se selecciona de manera independiente del grupo que consiste en hidrógeno, halógeno, hidroxi, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, ciano, nitro, amino, N-(alquil C₁₋₄)amino, N,N-di(alquil C₁₋₄)amino, N-(aril-alquil C₁₋₄)amino, alquilcarbonilamino C₁₋₆, cicloalquilcarbonilamino C₃₋₆, N-(alquil C₁₋₄)aminocarbonilo, N,N-di(alquil C₁₋₄)aminocarbonilo, alquiloxicarbonilamino C₁₋₄, cicloalquiloxicarbonilamino C₃₋₆, alquilsulfonamido C₁₋₄ y cicloalquilsulfonamido C₃₋₆; n es un número entero 1, 2 ó 3; R³ se selecciona del grupo que consiste en hidrógeno, halógeno, ciano, alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, cicloalquiloxi C₃₋₆, alquilotio C₁₋₄, cicloalquiltio C₃₋₆, amino, N-(alquil C₁₋₄)amino y N,N-di(alquil C₁₋₄)amino; uno de R⁴ y R⁵ es carboxilo, y el otro de R⁴ y R⁵ se selecciona del grupo que consiste en hidrógeno, fluoro, alquilo C₁₋₄ y haloalquilo C₁₋₄; R⁶ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₄; y R⁷ se selecciona del grupo que consiste en hidrógeno y alquilo C₁₋₄; o una sal farmacéuticamente aceptable de esta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201911049982 | 2019-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR120679A1 true AR120679A1 (es) | 2022-03-09 |
Family
ID=73790062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200103391A AR120679A1 (es) | 2019-12-04 | 2020-12-04 | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR120679A1 (es) |
CL (1) | CL2022001453A1 (es) |
EC (1) | ECSP22040834A (es) |
PT (1) | PT4069360T (es) |
TW (1) | TW202134223A (es) |
WO (1) | WO2021110883A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
EP4255565A1 (en) * | 2020-12-04 | 2023-10-11 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
WO2023164183A1 (en) * | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) * | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164181A1 (en) * | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
US20230338392A1 (en) | 2022-04-22 | 2023-10-26 | Albireo Ab | Subcutaneous administration of an asbt inhibitor |
WO2023237728A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
US20240067617A1 (en) | 2022-07-05 | 2024-02-29 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2024044183A1 (en) * | 2022-08-22 | 2024-02-29 | Enanta Pharmaceuticals, Inc. | Fused heterobicyclic antiviral agents |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI106800B (fi) | 1990-12-06 | 2001-04-12 | Hoechst Ag | Menetelmä uusien terapeuttisesti käyttökelpoisten dimeeristen sappihappojohdannaisten valmistamiseksi |
US5430116A (en) | 1991-12-20 | 1995-07-04 | Hoechst Aktiengesellschaft | Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
ES2111092T3 (es) | 1992-06-12 | 1998-03-01 | Hoechst Ag | Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. |
ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
TW289020B (es) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
TW289757B (es) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
TW289021B (es) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
WO1996008484A1 (en) | 1994-09-13 | 1996-03-21 | Monsanto Company | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
DE69734100D1 (de) | 1996-03-11 | 2005-10-06 | G D Searle Llc St Louis | Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme |
AU3940897A (en) | 1996-07-24 | 1998-02-10 | Zumtobel Staff Gmbh | Adapter for a retaining means used to secure a built-in lamp in a mounting hole,or retaining means or built-in lamp provided with such an adapter |
DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
IL131872A0 (en) | 1997-03-11 | 2001-03-19 | Searle & Co | Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors |
DK0864582T3 (da) | 1997-03-14 | 2003-09-29 | Aventis Pharma Gmbh | Hypolidemiske 1,4-benzothiazepin-1,1-dioxider |
GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
KR20010102965A (ko) | 1998-12-23 | 2001-11-17 | 윌리암스 로저 에이 | 심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용 |
IL143938A0 (en) | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
US6458851B1 (en) | 1998-12-23 | 2002-10-01 | G. D. Searle, Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
EA200100704A1 (ru) | 1998-12-23 | 2002-02-28 | Джи.Ди.Сирл Ллс | Комбинация для применения по сердечно-сосудистым показаниям |
ATE240120T1 (de) | 1998-12-23 | 2003-05-15 | Searle Llc | Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen |
CN1195748C (zh) | 1999-02-12 | 2005-04-06 | G.D.瑟尔有限公司 | 具有作为回肠胆汁酸转运和牛磺胆酸摄取抑制剂活性的新的1,2-苯并硫氮杂 |
DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
NZ531796A (en) | 2001-09-08 | 2005-10-28 | Astrazeneca Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment of hyperlipidaemia |
GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
ATE531701T1 (de) | 2002-08-28 | 2011-11-15 | Asahi Kasei Pharma Corp | Neue quaternüre ammoniumverbindungen |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
US9295677B2 (en) | 2008-02-26 | 2016-03-29 | Qing Bile Therapeutics Inc. | Polyhydroxylated bile acids for treatment of biliary disorders |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
CN106456997B (zh) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | 用于减少或预防肝性脂肪变性的组合物和方法 |
KR101674806B1 (ko) | 2014-10-20 | 2016-11-10 | 씨제이헬스케어 주식회사 | 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도 |
KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
RU2750937C2 (ru) | 2016-02-09 | 2021-07-06 | Альбирео Аб | Пероральный состав холестирамина и его применение |
ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
AU2019232477A1 (en) * | 2018-03-09 | 2020-09-10 | Elobix Ab | Process for the preparation of elobixibat |
US10793534B2 (en) * | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3100113A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2020161217A1 (en) | 2019-02-06 | 2020-08-13 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
JP7504110B2 (ja) | 2019-02-06 | 2024-06-21 | アルビレオ・アクチボラグ | ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
-
2020
- 2020-12-04 AR ARP200103391A patent/AR120679A1/es unknown
- 2020-12-04 WO PCT/EP2020/084567 patent/WO2021110883A1/en active Application Filing
- 2020-12-04 PT PT208211417T patent/PT4069360T/pt unknown
- 2020-12-04 TW TW109142972A patent/TW202134223A/zh unknown
-
2022
- 2022-05-19 EC ECSENADI202240834A patent/ECSP22040834A/es unknown
- 2022-06-02 CL CL2022001453A patent/CL2022001453A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202134223A (zh) | 2021-09-16 |
ECSP22040834A (es) | 2022-06-30 |
PT4069360T (pt) | 2024-03-06 |
WO2021110883A1 (en) | 2021-06-10 |
CL2022001453A1 (es) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR120679A1 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar | |
AR120683A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
AR120682A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar | |
AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
AR120674A1 (es) | Compuestos de benzotiazepina y su uso como ácido biliar | |
AR120676A1 (es) | Compuestos de benzoti(di)azepina y su uso como ácido biliar | |
CL2021001934A1 (es) | Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar. | |
CO2022007172A2 (es) | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar | |
CL2018002358A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR084070A1 (es) | Inhibidores del bromodominio y usos de los mismos | |
CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
RU2008123388A (ru) | Соединения и композиции в качестве модуляторов lxr | |
EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
AR070573A1 (es) | Derivados de 5,6 - bisaril -2- piridina - carboxamida, su preparacion, un medicamento y una composicion farmaceutica en base al compuesto, y la utilizacion del compuesto para la preparacion de un medicamento | |
DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
PE20081703A1 (es) | Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
CL2011001050A1 (es) | Compuesto 2-metil-1-(fenilsulfonil)-4-(piperazin-1-il)-1h-bencimidazol, que es ligando de 5-hidroxitriptamina-6; su composicion farmaceutica; modulador de la actividad de 5-ht6; su uso en el tratamiento de trastornos del sistema nervioso central, tal como psicosis, ansiedad, depresión, epilepsia, entre otros. | |
AR071780A1 (es) | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos | |
AR114918A1 (es) | Compuestos de benzotia(di)azepinas y su uso como moduladores de ácidos biliares | |
AR118025A1 (es) | Compuestos de benzotiazepina y su uso como moduladores de ácido biliar |